Sign Up
Ready to replace complexity with clarity?
Answer your real world compliance questions (limited time) and save thousands in legal fees and avoided fines.
Automate Compliance TodayUS states A to Z: marijuana, THCA, delta-8, delta-9, delta-10, HHC
State-by-state mapMost read countries: marijuana, CBD and hemp status
All countries on the globeSubstances: status in every state for each one
Compare all substancesFederal hemp redefinition: P.L. 119-103, div. B, sec. 2019
Nov 12, 2026
Applies only to cannabinoids the plant cannot naturally produce.
Dec 11, 2026
The total-THC test, the 0.4 mg per container cap and the exclusion of converted cannabinoids start.
Latest regulatory actions, updated daily
All regulatory actionsHeadlines and the first four sentences are free. Full write-ups, impact reasoning and the archive are for members.
Member · $99/mo
Every rule change, the day it is made.
The price will rise. Join now and $99 a month stays your rate for life.
Become a memberOr read free: every action opens 30 days after it is published. Sign in with email
By topic
Licensing and permitsPackaging and labelingLab testing and QARetail complianceAdvertising and marketingBanking and paymentsTaxesShipping and logisticsTravel and transportLitigationSOPsFor your role
Regulators and agenciesBrands and operatorsRetailers and smoke shopsCultivatorsProcessorsLawyers and complianceInvestorsConsumers and travelersThe Regulator Brief · newsletter
Every rule change that matters, every Monday.
Free: the Monday brief, and every action 30 days after it is published.
Members: the paid weekly, daily alerts and every write-up.
Read by regulators, operators, lawyers and founders.
Cannabis lawyers
Licensed by state. Listings are not endorsements.
By state
Software and services
Compared by fit, never ranked.
Categories
For companies and firms
Be the listing operators and regulators find.
Software and services
Verified, $49/mo: domain-verified badge, your website link, a quote.
Featured, from $399/mo: labeled Featured in your category, monthly release notes.
Lawyers and firms
Claimed, $75/yr: Claimed badge and your firm's website link.
Featured, $199/mo: labeled Featured on your profile.
Claim your companyClaim a lawyer listingPlacements, flat monthly fee
State and country page sponsorshipsExclusive slot on a legality page and its postsRegulator Brief sponsorshipPresenting sponsor or mid-issue banner, free editionMember brief sponsor slotThe paid weekly, read by members onlyFeatured directory placementLabeled Featured in a software categoryCategory sponsorshipOwn one directory category across the sitePaid guest postsLabeled Paid guest post, sponsored linksWrite and partner
Pitch a paid guest postRead guest postsBecome an affiliateSend a tip or correctionContact the teamWho reads it
Regulators at federal, state and county agencies, plus the operators, lawyers and founders they regulate.
Get the media kitSee open placementsSubstances
US states, map and A to ZCountriesFederal hemp 2026: Nov 12 and Dec 11Compound index, every stateTravelling with cannabis or hempMembers get the daily alert email and every full write-up the morning it is published. Every action is free to read 30 days later.
For your role
All news and analysisGuidesAnalysisFAQsTemplates and SOPsCourt filing recapsNews by state and countrySoftware and services: Verified $49/mo, Featured from $399/mo. Lawyers and firms: Claimed $75/yr, Featured $199/mo. Listings are not endorsements.
Regulatory journalism, not legal advice. How we report

Quick Answer
The Drug Enforcement Administration's proposed 2027 aggregate production quotas, published Nov. 10, 2026 (FR Doc. 2026-22843, Docket No. DEA-1730P, 91 FR 72566), say the first quotas for schedule III marijuana will come in a separate Federal Register notice. Comments on the schedule I and II proposal are due on or before Dec. 10, 2026. The notice gives no date for the schedule III proposal and does not say how big it will be.
On this page
An aggregate production quota, or APQ, is the total amount of a controlled substance DEA allows to be manufactured in the United States in a calendar year. Under 21 U.S.C. 826, DEA sets APQs for each basic class of controlled substance in schedules I and II, then hands out individual manufacturing quotas to registered manufacturers. The individual quotas cannot add up to more than the aggregate.
The 2027 proposal sets these schedule I figures for cannabis substances, in grams:
DEA says that table covers only schedule I marijuana, marijuana extract and delta-9-THC (drug codes 7360, 7350 and 7370). The schedule III versions of the same substances have their own drug codes: 7362 for marijuana, 7353 for marijuana extract and 7386 for naturally derived delta-9-THC. For those, DEA wrote, "A separate notice will be published in the Federal Register" once the proposed amounts are determined. DEA says it is still registering schedule III manufacturers and distributors and choosing data sets to estimate legitimate need.
Two processes now run side by side, and they bind different people. The Dec. 10 comment window governs research and pharmaceutical supply that stays in schedule I. For a manufacturer that wants to make product for state medical programs under a DEA registration, the number that will matter is the one in the schedule III notice that has not been published yet.
The split traces to the April 2026 rescheduling order. The final order at 91 FR 22714 (FR Doc. 2026-08176, effective April 28, 2026) placed three entries in schedule III: marijuana, marijuana extract and naturally derived delta-9-THC, each only when it is in an FDA-approved product or subject to a state medical marijuana license. Everything else, including unlicensed and bulk marijuana, "remains a schedule I controlled substance." That is the line behind the two-tier federal market for medical and recreational cannabis.
| Item | Schedule I marijuana | Schedule III marijuana |
|---|---|---|
| What it covers | Marijuana, extract and delta-9-THC outside an FDA-approved product or a state medical marijuana license, including unlicensed and bulk material | Marijuana, extract and naturally derived delta-9-THC in an FDA-approved product or subject to a state medical marijuana license |
| DEA drug codes | 7360 marijuana, 7350 marijuana extract, 7370 delta-9-THC | 7362 marijuana, 7353 marijuana extract, 7386 naturally derived delta-9-THC |
| 2027 quota status | Proposed Nov. 10, 2026: 6,675,000 g marijuana; 1,000,000 g extract; 1,523,040 g delta-9-THC. Comments due Dec. 10, 2026 | Not yet proposed. DEA says a separate notice will follow; no date given |
| Legal hook for the quota | 21 U.S.C. 826 (schedules I and II) | Single Convention quota obligation, as described in the April 2026 order and the APQ notice |
| Registration path | Standard DEA schedule I registration | Expedited registration for state medical marijuana licensees under 21 CFR 1301.13(k), limited to the scope of the state license |
This is the part the wire stories skipped. The quota statute, 21 U.S.C. 826, reaches schedules I and II. Schedule III drugs normally carry no production ceiling. The April order explains why rescheduled marijuana does: the 1961 Single Convention on Narcotic Drugs requires licensed manufacturers of its schedule I drugs, which include cannabis, to obtain quotas. The order says state-licensed marijuana will have to meet those treaty quota requirements. The order itself rested on 21 U.S.C. 811(d)(1), which lets the government schedule a drug by order to carry out treaty obligations.
The APQ notice repeats the treaty rationale but does not cite a statutory provision for setting quotas on a schedule III substance. That leaves an open question for registrants: rescheduled medical marijuana keeps a schedule II style production ceiling, but the mechanics (who applies, by when, and how individual quotas are cut if demand exceeds the aggregate) have not been published.
Nothing about the schedule III quota is fixed: no number, no date, no chosen data source. A quota sized to research demand would look very different from one sized to state medical program sales.
The broader rescheduling case is also open. The administrative hearing record closed with final briefs on Nov. 5, as covered in our report on the rescheduling hearing record. As of Nov. 18, DEA's rescheduling docket page showed no recommended decision from the administrative law judge. DEA's own position on the record is laid out in DEA's schedule III post-hearing brief.
The quota will meter a system that states are entering on very different terms. In California, the Department of Cannabis Control adopted emergency regulations on June 5, 2026 letting retailers holding a combined A and M license split it so the medical side can seek DEA registration; the follow-on rulemaking, DCC-2026-04-R, is covered in our piece on California's A/M license split. Even so, Marijuana Moment reported on Nov. 11 that DEA sent orders to show cause to at least some California applicants, citing sources and documents it reviewed, on the ground that California does not require a physician's written certification.
In Minnesota, Marijuana Moment reported on Oct. 30 that DEA issued an order to show cause to a Minneapolis dispensary, saying the state's dual-purpose license falls outside the federal definition of a state medical license. The same report said businesses in states such as Florida and Texas were among the more than 900 approved. Operationally, a state's license design now decides whether its operators are inside the schedule III supply chain at all, before any quota question arises.
It is the total amount of a schedule I or II controlled substance DEA allows to be manufactured in the United States in a year, set under 21 U.S.C. 826. Individual manufacturing quotas for registered manufacturers are allotted from it and cannot exceed it.
Yes, according to DEA. Its proposed 2027 quotas notice says a separate Federal Register notice will propose quotas for schedule III marijuana, marijuana extract and naturally derived delta-9-THC (drug codes 7362, 7353 and 7386). No date has been given.
Comments on the proposed 2027 schedule I and II quotas (Docket No. DEA-1730P, published Nov. 10, 2026) are due on or before Dec. 10, 2026. Electronic comments close at 11:59 p.m. Eastern that day.
Not directly. Under the April 2026 order, only marijuana in FDA-approved products or subject to a state medical marijuana license moved to schedule III. Adult-use marijuana remains in schedule I federally, and the coming schedule III quotas would cover medical marijuana handled by DEA registrants. Talk to your counsel.
This is regulatory journalism, not legal advice. Talk to your counsel.